Abstract
O lfactory dysfunction, especially impairment in odor identification, has been well established in several neurodegenerative conditions. In particular, the presence of notable deficits in both Alzheimer disease (AD) and Parkinson disease (PD) has been demonstrated repeatedly. 1 In AD, progressive deficits have been shown in patients with early dementia, 2 in patients with suspected preclinical disease, 3 in nondemented individuals with and without mild cognitive changes who are considered "at risk" for AD based on ApoE genotype, 4, 5 and in nondemented first degree relatives of patients with Alzheimer disease. 6 In PD, prominent deficits are also well established in early disease 7 and may be the most prevalent early impairment, even more so than the "hallmark" symptom of tremor. 8 Olfactory functioning has not been well studied in other neurodegenerative diseases, though there is a growing body of research that has generally shown more modest deficits in Huntington disease, 9 progressive supranuclear palsy, 10 and vascular dementia. [11] [12] [13] Given the overlap of the clinical symptoms and neuropathology of diffuse Lewy body disease (DLBD) with both AD and PD, 14 the presence of olfactory deficits in DLBD is likely. To date, however, there is only one published report of olfactory functioning in patients with DLBD, with only cursory evaluation of odor detection abilities. 15 McShane et al 15 report data from the Oxford Project to Investigate Memory and Ageing (OPTIMA), a longitudinal study of 92 patients (and 94 controls) with full clinical datasets and neuropathologically confirmed neurodegenerative dementias. Clinical examination of olfaction included asking patients whether they could detect an odor from a sniff bottle containing lavender water. Those who were unable to detect the scent were considered anosmic. Results of this study showed that anosmia was more prevalent in patients with DLBD (41%) than in controls (6%) or in patients with AD (16%). In patients with DLBD, anosmia was not associated with the degree of concurrent Alzheimer pathology (i.e., the severity of neurofibrillary pathology), arguing against a synergistic effect.
Although the measurement of olfaction in the OPTIMA study was extremely limited, the data are intriguing and suggest that additional investigation of olfactory functioning in DLBD is warranted. Furthermore, other pathologic studies support the likelihood of olfactory impairments in DLBD. GomezTortosa et al 16 demonstrated the presence of Lewy bodies in the entorhinal cortex, a region of the brain presumably involved in the processing of olfactory information. Spongiform changes have also been observed in the entorhinal cortex in DLBD. 17 In addition, Piao et al 18 discovered ␣-synuclein-immunoreactive inclusions and Lewy neurites in nerve cell bodies of the olfactory nucleus in five of six patients with DLBD, and in the glial cells of the olfactory bulb in four of six patients.
The current preliminary study sought to further describe olfactory functioning in patients with DLBD by assessing odor identification performance in these patients, as odor identification tasks have been found to be more sensitive indicators of neurodegeneration than odor detection tasks. 19 In addition, we investigated the clinical utility of these tests for distinguishing clinic patients with DLBD from those with AD.
METHODS

Patients
All patients had been referred by their physicians to our general medical centerbased Memory and Cognitive Assessment Program for a neuropsychologic evaluation.
Patients With Diffuse Lewy Body Disease
Patients with diffuse Lewy body disease were included in this series if they met criteria for a diagnosis of probable DLBD according to McKeith et al's consensus criteria. 17 The group presented here represents all patients meeting this criteria (six outpatients and three inpatients) from our clinical database of 138 patients with dementia who had completed olfactory testing as part of their neuropsychological examination. None of the patients were considered to be delirious or acutely confused at the time of the examination, and none had other significant medical illnesses that could account for their cognitive or olfactory impairments. None had undergone nasal surgery or suffered significant head injuries in the past. Seven of nine patients underwent neuroimaging, and none showed evidence of other neurologic disease that could account for their dementias. Table   TABLE 1 
Patients With Alzheimer Disease
From our clinical database, 38 patients met criteria for probable AD based on NINCDS-ADRDA consensus criteria. 20 Of these patients, nine outpatients were selected as a comparison group. The AD patients selected were matched to the DLBD group to the extent possible on important characteristics, including age, gender, educational level, level of dementia based on both Clinical Dementia Rating (CDR) 21 summary scores and "total box scores" 22 (i.e., total sum of each CDR component score), and level of overall cognitive functioning as determined by Mini Mental State Examination 23 total scores (Table 2) . Smoking history was not taken into account given that prior work from our group has not shown any significant impact of smoking on odor identification performance. 24 None met criteria for probable or possible DLBD based on the McKeith et al criteria, probable or possible vascular dementia based on DSM-IV, 25 NINDS-AIRENS, 26 or ADDTC 27 criteria, or fronto-temporal dementia based on Neary et al's consensus criteria. 28 All had Hachinski Ischemia Scale 29 scores of less than or equal to 4. None were delirious or acutely confused at the time of the examination, and none had other significant medical illnesses that could account for their cognitive or olfactory impairments. Patients with histories of significant head injuries or who had undergone nasal surgery were excluded. Selection and matching of the AD patients was done without knowledge of individual odor identification performance.
Materials
All patients were administered the Brief Smell Identification Test, 30 a 12-item, multiple choice, scratch-and-sniff, odor identification test. Although the test was designed to be self-administered, the BSIT was administered to each patient by the examiner to minimize the cognitive demands of the task. That is, the examiner scratched the sense strip, read the choices aloud, instructed the patient where on the card to sniff if necessary, and filled in the patient's response for each item. Patients were strongly encouraged to provide responses for each item. However, two DLBD patients and one AD patient found the task aversive given that they were insistent that they were unable to detect an odor, and these patients refused to complete the entire task. One AD patient also had a faulty BSIT booklet with a missing item. Therefore, the BSIT scores were reported as the percentage of correct responses of the items completed to include all patients and to minimize the likelihood of a bias in the sample toward patients with more intact olfactory functioning.
RESULTS
There were no statistically significant differences between the dementia groups in 
DLBD patients AD patients
Gender: M: Qualitative review of the data revealed that BSIT performance in the DLBD group ranged from 0% correct (0/4) to 50% correct (6/12). Five of nine patients scored at or near chance level (Յ 4 correct), reported detecting no scent, and were considered completely anosmic. The group of four patients scoring 5 to 6/12 correct included the three youngest patients in the group (all aged less than 70 years), and the scores of those three patients were at or below the third percentile for their age/gender group based on published norms. 30 Only one patient in the DLBD group obtained a score on the BSIT which was within one standard deviation of the mean for her normative age/gender group (6/12 correct). In the AD group, BSIT scores ranged from 25% correct (3/12) to 83% correct (10/12). Only one AD patient was considered completely anosmic, and only one other patient performed below one standard deviation of his normative age/gender group.
DISCUSSION
This is the first report to document odor identification deficits in patients with DLBD, as well as the first to demonstrate the clinical utility of odor identification tests in differentiating DLBD from AD. In our sample, patients with DLBD exhibited greater impairment on odor identification testing than patients with AD. All but one of the DLBD patients demonstrated significant olfactory deficits, with over half showing anosmia. In contrast, although the mean of the AD group was below average compared with age and gender corrected published norms, only two AD patients demonstrated significant odor identification deficits, and only one of the two appeared completely anosmic. Of note, the groups were well matched in terms of age, gender, educational level, level of cognitive impairment, and level of dementia severity, suggesting that factors such as overall cognitive impairment or functional decline cannot account for the differences between the groups.
There are several limitations to our study. First is the lack of pathologic verification of the disease process. As with any antemortem series lacking pathology data, the possibility that the patients presented here had other conditions which may account for their deficits is worth considering. This limitation is likely to be of greater concern in the diagnosis of AD than in DLBD, as clinicopathologic correlation studies examining the diagnostic accuracy of the McKeith consensus criteria have found the criteria to be highly specific, though insensitive. 31 In contrast, the specificity of the NINCDS-ADRDA AD criteria has been shown to be poorer. 31 In an attempt to minimize the likelihood of overdiagnosing AD, we were highly selective in choosing the patients presented here and included only those who did not meet criteria for possible or probable dementia of other types, who had Hachinski scores of less than or equal to 4, and who had no evidence of other neurologic disease when imaging studies were available (as was the case in 7/9 patients).
Another potential limitation includes our small sample size. We were able to identify only nine patients with olfactory data from our clinical database of 138 patients with dementia who met criteria for probable DLBD. The small number of DLBD patients in our database may reflect several factors, including the insensitivity of the diagnostic criteria as stated previously, or some selection bias based on the nature of our clinic. It is possible that patients in our area with DLBD may be more likely to present to a nearby Westervelt et al primary psychiatric center with its own memory disorders clinic (particularly those presenting with hallucinations) or to a local primary movement disorders office which also has its own neuropsychology group, rather than our general medical center. In particular, most of the patients in our sample had fairly subtle parkinsonism, and it is unclear whether patients presenting with more prominent movement disorders show the same frequency and degree of olfactory impairment as the patients who presented to our center. Nevertheless, there was a fair degree of homogeneity in the DLBD sample in terms of olfactory performance, despite some heterogeneity in their presenting symptoms (Table 1 ). In terms of the AD patients, we suspect that the olfactory performance of the patients presented here is fairly representative of that in AD patients as a whole, as an analysis of the BSIT performance of the AD patients who were matched to the DLBD group revealed no statistically significant differences compared with the unselected 29 AD patients in our database who met the same inclusion criteria. The decision to include three inpatients with DLBD in this series was carefully considered given concerns that a hospitalized patient may demonstrate DLBD symptoms as a result of acute mental status changes. We selected only patients in whom the neuropsychologic evaluation and recent hospital course argued against the presence of a current delirium. This raises the larger issue of consideration of DLBD in the differential diagnosis of hospitalized patients in whom the etiology of hallucinations and other mental status changes is uncertain. Specifically, fluctuations in level of alertness/mental status and hallucinations are characteristic of delirium, as well as DLBD. In fact, the confusional episodes of DLBD may be indistinguishable from a systemic delirium. 32 Thus, particularly in hospitalized patients with histories of cognitive decline, parkinsonism, and hallucinations or confusional episodes that predate their admission, a diagnosis of DLBD is worth considering, especially if other causes for delirium have not been identified. Of note, like other patients with a dementia, patients with early DLBD, especially those living alone, may also be at greater risk for poor nutrition and self-care, leading to greater likelihood of illness, falls, and hospitalization. Accurate diagnosis of these patients in such a setting could have important treatment implications, as strong dopamine antagonists are contraindicated in DLBD, but are often used to treat hallucinations and other delirium symptoms. 33 In our limited experience in using olfactory measures in delirious patients without suspected DLBD, olfaction appears to be relatively preserved, though further research is needed to determine whether these tests may be useful in distinguishing delirium from a confusional episode of DLBD. Our clinic has routinely used the BSIT in the assessment of patients with possible dementia (primarily outpatients) for approximately 2 years. Although the literature shows without exception that patients with AD tend to have olfactory deficits, our clinical experience and the data presented here suggest that total anosmia is fairly infrequent in patients with mild to moderate probable AD. McShane et al 15 suggest that misdiagnosis may account for previous reports of impaired odor detection in AD patients. This possibility is worth considering given that consensus on the clinical criteria for DLBD is relatively recent, and the three cardinal features of probable DLBD do not necessarily exclude a diagnosis of AD. Therefore, prior published studies of olfaction in AD patients may have included patients with DLBD. However, differences in the degree of impairment, as found by our group, should be underscored. Patients with AD may not be as likely to show complete anosmia, and hence, may not appear as impaired on a supra-threshold detection task such as that used by McShane et al. However, this does not exclude the possibility of less dramatic, but nevertheless meaningful, olfactory deficits in AD when compared with healthy controls. Our decision to have the examiner administer the BSIT to the 97 COGNITIVE AND BEHAVIORAL NEUROLOGY patients may also have minimized the cognitive demands of the task and optimized performance.
The cause of olfactory impairments in DLBD is unclear. DLBD and AD tend to affect similar neuroanatomic regions, and neuropathologic changes have been shown in central olfactory processing areas (e.g., entorhinal cortex) and peripheral structures (e.g., olfactory bulbs) in both AD and DLBD. 16, 17, 34, 35 These pathologic changes may account for the olfactory deficits present in both of these disorders, but does not explain the apparent difference in the degree of impairment. As stated above, McShane et al's 15 findings do not support the likelihood that this difference reflects an additive effect of AD and Lewy body pathology in patients with DLBD. Whether other critical central and/or peripheral olfactory processing areas are affected (or more affected) in DLBD but not in AD has not yet been demonstrated, but remains a possibility. Differences in affected neurotransmitter systems may also underlie these discrepancies. McShane et al entertain these latter two considerations in discussing both the potentially important role of dopamine in olfaction (as the dopaminergic system is more significantly affected in DLBD than in AD), as well as their findings that greater involvement of the cingulate in DLBD was associated with anosmia. Finally, the possibility that the anatomic location of pathologic involvement may not be sufficient to cause anosmia is worth considering. That is, the presence or degree of olfactory deficits may be more dependent on the nature of the pathology in certain anatomic regions than the mere presence of pathology in those areas.
In sum, our preliminary results are in keeping with the findings of McShane et al 15 -that anosmia may be more prevalent in people with DLBD than in people with Alzheimer disease. Thus, although olfaction is often ignored in neurologic and neuropsychological evaluations, these brief noninvasive measures may prove to be useful in the differential diagnosis of dementia. Given the frequency of concomitant pathologic findings of AD in DLBD, identification of a clinical sign, which may be relatively specific to DLBD and not masked by AD pathology, may be extremely valuable. 36 In addition, olfactory testing may offer a more objectively quantifiable indicator of DLBD than can be obtained for some of the diagnostically necessary clinical criteria such as hallucinations and fluctuations. 37 
